The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy

Lijie Zhai, Mahua Dey, Kristen L. Lauing, Galina Gritsina, Rajwant Kaur, Rimas V. Lukas, M. Kelly Nicholas, Alfred W. Rademaker, Carlos R. Dostal, Robert H. McCusker, Jeffrey J. Raizer, Andrew T. Parsa, Orin Bloch, Derek A. Wainwright

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy. GBM is the most common form of malignant glioma in adults. Despite aggressive surgical resection, irradiation and chemotherapy, patients with GBM have a median survival of only 14.6 months after diagnosis. This poor outcome has led to the search for more effective treatments, including immunotherapy. However, the identification of parameters that proactively stratify GBM patients who have the potential for therapeutic benefit has been challenging. Given recent observations demonstrating high indoleamine 2,3 dioxygenase 1 (IDO1) expression in GBM, the immunosuppressive impact of IDO1-mediated Trp catabolism, as well as active transport of Trp and the IDO1-downstream Trp catabolite, Kyn, across the blood brain barrier, we hypothesized that peripheral blood analysis of this pathway would provide diagnostic utility. When comparing individuals without tumors to GBM patients prior to surgical resection, or at the 48 hour (48 h) and ≥10 week (10w+) postoperative time points, Trp levels were significantly decreased (p < 0.0002). Similarly, Kyn levels were decreased in the pre- and 48 h postoperative GBM patients (p < 0.0001), while there was no difference between individuals without tumors and 10w+ GBM patients. Interestingly, those 10w+ patients with a high Kyn/Trp ratio (≥9.5) had a mean overall survival (OS) of 23.6 ± a standard error of 6.8 months, compared to an OS of 38.7 ± 4.9 months for patients with lower Kyn/Trp values. Since the 10w+ blood draw and analyses occurred prior to patient enrollment in the heat shock protein peptide complex-96 clinical trial, these novel data suggest that the late Kyn/Trp index may be a relevant clinical benchmark, providing prognostic value for GBM patients who are enrolled in immunotherapeutic regimens.

Original languageEnglish (US)
Pages (from-to)1964-1968
Number of pages5
JournalJournal of Clinical Neuroscience
Volume22
Issue number12
DOIs
StatePublished - Dec 2015
Externally publishedYes

Fingerprint

Kynurenine
Glioblastoma
Tryptophan
Immunotherapy
Indoleamine-Pyrrole 2,3,-Dioxygenase
Survival
Tryptophan Oxygenase
Benchmarking
Active Biological Transport
Immunosuppressive Agents
Heat-Shock Proteins
Blood-Brain Barrier
Individuality
Glioma
Neoplasms
Clinical Trials

Keywords

  • Brain tumor
  • Diagnostic
  • Glioblastoma multiforme
  • Immunosuppression
  • Kynurenine
  • Metabolism
  • Tryptophan

ASJC Scopus subject areas

  • Surgery
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Zhai, L., Dey, M., Lauing, K. L., Gritsina, G., Kaur, R., Lukas, R. V., ... Wainwright, D. A. (2015). The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. Journal of Clinical Neuroscience, 22(12), 1964-1968. https://doi.org/10.1016/j.jocn.2015.06.018

The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. / Zhai, Lijie; Dey, Mahua; Lauing, Kristen L.; Gritsina, Galina; Kaur, Rajwant; Lukas, Rimas V.; Nicholas, M. Kelly; Rademaker, Alfred W.; Dostal, Carlos R.; McCusker, Robert H.; Raizer, Jeffrey J.; Parsa, Andrew T.; Bloch, Orin; Wainwright, Derek A.

In: Journal of Clinical Neuroscience, Vol. 22, No. 12, 12.2015, p. 1964-1968.

Research output: Contribution to journalArticle

Zhai, L, Dey, M, Lauing, KL, Gritsina, G, Kaur, R, Lukas, RV, Nicholas, MK, Rademaker, AW, Dostal, CR, McCusker, RH, Raizer, JJ, Parsa, AT, Bloch, O & Wainwright, DA 2015, 'The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy', Journal of Clinical Neuroscience, vol. 22, no. 12, pp. 1964-1968. https://doi.org/10.1016/j.jocn.2015.06.018
Zhai, Lijie ; Dey, Mahua ; Lauing, Kristen L. ; Gritsina, Galina ; Kaur, Rajwant ; Lukas, Rimas V. ; Nicholas, M. Kelly ; Rademaker, Alfred W. ; Dostal, Carlos R. ; McCusker, Robert H. ; Raizer, Jeffrey J. ; Parsa, Andrew T. ; Bloch, Orin ; Wainwright, Derek A. / The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy. In: Journal of Clinical Neuroscience. 2015 ; Vol. 22, No. 12. pp. 1964-1968.
@article{314b999d558042b9ae77f59770a74d0a,
title = "The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy",
abstract = "We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy. GBM is the most common form of malignant glioma in adults. Despite aggressive surgical resection, irradiation and chemotherapy, patients with GBM have a median survival of only 14.6 months after diagnosis. This poor outcome has led to the search for more effective treatments, including immunotherapy. However, the identification of parameters that proactively stratify GBM patients who have the potential for therapeutic benefit has been challenging. Given recent observations demonstrating high indoleamine 2,3 dioxygenase 1 (IDO1) expression in GBM, the immunosuppressive impact of IDO1-mediated Trp catabolism, as well as active transport of Trp and the IDO1-downstream Trp catabolite, Kyn, across the blood brain barrier, we hypothesized that peripheral blood analysis of this pathway would provide diagnostic utility. When comparing individuals without tumors to GBM patients prior to surgical resection, or at the 48 hour (48 h) and ≥10 week (10w+) postoperative time points, Trp levels were significantly decreased (p < 0.0002). Similarly, Kyn levels were decreased in the pre- and 48 h postoperative GBM patients (p < 0.0001), while there was no difference between individuals without tumors and 10w+ GBM patients. Interestingly, those 10w+ patients with a high Kyn/Trp ratio (≥9.5) had a mean overall survival (OS) of 23.6 ± a standard error of 6.8 months, compared to an OS of 38.7 ± 4.9 months for patients with lower Kyn/Trp values. Since the 10w+ blood draw and analyses occurred prior to patient enrollment in the heat shock protein peptide complex-96 clinical trial, these novel data suggest that the late Kyn/Trp index may be a relevant clinical benchmark, providing prognostic value for GBM patients who are enrolled in immunotherapeutic regimens.",
keywords = "Brain tumor, Diagnostic, Glioblastoma multiforme, Immunosuppression, Kynurenine, Metabolism, Tryptophan",
author = "Lijie Zhai and Mahua Dey and Lauing, {Kristen L.} and Galina Gritsina and Rajwant Kaur and Lukas, {Rimas V.} and Nicholas, {M. Kelly} and Rademaker, {Alfred W.} and Dostal, {Carlos R.} and McCusker, {Robert H.} and Raizer, {Jeffrey J.} and Parsa, {Andrew T.} and Orin Bloch and Wainwright, {Derek A.}",
year = "2015",
month = "12",
doi = "10.1016/j.jocn.2015.06.018",
language = "English (US)",
volume = "22",
pages = "1964--1968",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "12",

}

TY - JOUR

T1 - The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy

AU - Zhai, Lijie

AU - Dey, Mahua

AU - Lauing, Kristen L.

AU - Gritsina, Galina

AU - Kaur, Rajwant

AU - Lukas, Rimas V.

AU - Nicholas, M. Kelly

AU - Rademaker, Alfred W.

AU - Dostal, Carlos R.

AU - McCusker, Robert H.

AU - Raizer, Jeffrey J.

AU - Parsa, Andrew T.

AU - Bloch, Orin

AU - Wainwright, Derek A.

PY - 2015/12

Y1 - 2015/12

N2 - We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy. GBM is the most common form of malignant glioma in adults. Despite aggressive surgical resection, irradiation and chemotherapy, patients with GBM have a median survival of only 14.6 months after diagnosis. This poor outcome has led to the search for more effective treatments, including immunotherapy. However, the identification of parameters that proactively stratify GBM patients who have the potential for therapeutic benefit has been challenging. Given recent observations demonstrating high indoleamine 2,3 dioxygenase 1 (IDO1) expression in GBM, the immunosuppressive impact of IDO1-mediated Trp catabolism, as well as active transport of Trp and the IDO1-downstream Trp catabolite, Kyn, across the blood brain barrier, we hypothesized that peripheral blood analysis of this pathway would provide diagnostic utility. When comparing individuals without tumors to GBM patients prior to surgical resection, or at the 48 hour (48 h) and ≥10 week (10w+) postoperative time points, Trp levels were significantly decreased (p < 0.0002). Similarly, Kyn levels were decreased in the pre- and 48 h postoperative GBM patients (p < 0.0001), while there was no difference between individuals without tumors and 10w+ GBM patients. Interestingly, those 10w+ patients with a high Kyn/Trp ratio (≥9.5) had a mean overall survival (OS) of 23.6 ± a standard error of 6.8 months, compared to an OS of 38.7 ± 4.9 months for patients with lower Kyn/Trp values. Since the 10w+ blood draw and analyses occurred prior to patient enrollment in the heat shock protein peptide complex-96 clinical trial, these novel data suggest that the late Kyn/Trp index may be a relevant clinical benchmark, providing prognostic value for GBM patients who are enrolled in immunotherapeutic regimens.

AB - We hypothesized that peripheral tryptophan (Trp) and/or kynurenine (Kyn) levels would provide prognostic value for physicians planning to enroll glioblastoma multiforme (GBM) patients in immunotherapy. GBM is the most common form of malignant glioma in adults. Despite aggressive surgical resection, irradiation and chemotherapy, patients with GBM have a median survival of only 14.6 months after diagnosis. This poor outcome has led to the search for more effective treatments, including immunotherapy. However, the identification of parameters that proactively stratify GBM patients who have the potential for therapeutic benefit has been challenging. Given recent observations demonstrating high indoleamine 2,3 dioxygenase 1 (IDO1) expression in GBM, the immunosuppressive impact of IDO1-mediated Trp catabolism, as well as active transport of Trp and the IDO1-downstream Trp catabolite, Kyn, across the blood brain barrier, we hypothesized that peripheral blood analysis of this pathway would provide diagnostic utility. When comparing individuals without tumors to GBM patients prior to surgical resection, or at the 48 hour (48 h) and ≥10 week (10w+) postoperative time points, Trp levels were significantly decreased (p < 0.0002). Similarly, Kyn levels were decreased in the pre- and 48 h postoperative GBM patients (p < 0.0001), while there was no difference between individuals without tumors and 10w+ GBM patients. Interestingly, those 10w+ patients with a high Kyn/Trp ratio (≥9.5) had a mean overall survival (OS) of 23.6 ± a standard error of 6.8 months, compared to an OS of 38.7 ± 4.9 months for patients with lower Kyn/Trp values. Since the 10w+ blood draw and analyses occurred prior to patient enrollment in the heat shock protein peptide complex-96 clinical trial, these novel data suggest that the late Kyn/Trp index may be a relevant clinical benchmark, providing prognostic value for GBM patients who are enrolled in immunotherapeutic regimens.

KW - Brain tumor

KW - Diagnostic

KW - Glioblastoma multiforme

KW - Immunosuppression

KW - Kynurenine

KW - Metabolism

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=84948713309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948713309&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2015.06.018

DO - 10.1016/j.jocn.2015.06.018

M3 - Article

C2 - 26279502

AN - SCOPUS:84948713309

VL - 22

SP - 1964

EP - 1968

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 12

ER -